Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative FOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Resectable Pancreatic Cancer
NCT02243007Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2014
- Primary completion
- Jun 2016
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, irinotecan, oxaliplatin, gemcitabine and 1 more in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Survival Rate at 18 Month. Started Sep 2014; status: terminated.
02
Drugs
fluorouracilfolinic acidirinotecanoxaliplatingemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02243007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243007.